fat is an angry substance Nov 17, 2009
Then they injected the mice with macrophages lacking a surface protein called TLR4 ... Olefsky concludes that TLR4 mediates the immune system's response to fat ... He says that some fatty acids look like the bacterial invaders that TLR4 senses, prompting normal macrophages to mistake fatty acids for the enemy and turn on inflammation. (Harper's Magazine)
3M announces drug licensing deal Nov 10, 2009
3M Drug Delivery Systems said the deal with Cranbury, N.J.-based VaxInnate involves a 3M toll-like receptor (TLR) agonist, a drug that the company says has shown promise as vaccine adjuvants additives that increase vaccine potency or efficiency. Under the terms of the non-exclusive licensing agreement, 3M provides its TLR agonists to VaxInnate for an undisclosed licensing fee, in addition to milestone and royalty payments. (Twin Cities Business Journal, MN)
Final 12 Month Clinical Data from 5,000 Patients in Worldwide e-HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Sep 23, 2009
1 percent at 12 months with a follow-up rate of 92 percent, a target lesion revascularization (TLR) rate of 4 ... The 12-month follow-up from these 1,243 patients with diabetes mellitus showed a low TLR rate of 4. (PR Newswire)
Regulating The Regulators: New Therapeutic Approach Against Cancer Sep 22, 2009
For example, a Toll-like receptor (TLR) agonist, called imiquimod, which activates dendritic cells, is in clinical use as a topical application for basal cell carcinoma. In addition, a number of TLR agonists have been evaluated in clinical trials as an adjuvant for cancer vaccines ... However there have also been disappointing results from clinical trials involving TLR agonists. (Science Daily)
TSX Venture Exchange Daily Bulletins for September 11, 2009 Sep 12, 2009
CUSIP Number: 152379707 (new) TSX-X -------------------------------------------------------------------------- CORBAL CAPITAL CORP. ("ISD") (formerly Corbal Capital Corp. (RBL.P")) BULLETIN TYPE: Qualifying Transaction-Completed, Private Placement-Non- Brokered, Resume Trading, New Symbol BULLETIN DATE: September 11, 2009 TSX Venture Tier 2 Company TSX Venture Exchange has accepted for filing the Company's Qualifying Transaction described in its Filing Statement dated July 14, 2009. As a result,... (CCNMatthews Press Releases)
Scripps research scientists find key culprits in lupus Jun 30, 2009
In a study published in the Early Edition of the Proceedings of the National Academy of Sciences (PNAS) the week of June 29, 2009, Scripps Research Professor of Immunology and Microbial Science Dwight Kono and colleagues demonstrate that three proteins, called Toll-like receptors (TLRs), are necessary for this autodestruction to occur. TLRs may thus provide effective targets for the development of new treatments for lupus, as well as other autoimmune diseases ... TLRs are proteins found in... (EurekAlert!)
The Steve Irwin should be torpedoed by a Japanese naval vessel, and any and all... Jun 1, 2009
November 29, 2008 In response to: Animal Planet's Whale Wars Rocks The Boat TLR commented. You have got to be kidding,the sea shepards are nothing more than maniplulative liars and P.E.T.A freaks. (Multichannel News)
Angiotech Pharmaceuticals, Inc. - New study shows that Zilver(R) PTX(TM) effectively treats blockages in critical thigh artery Apr 15, 2009
The corresponding event-free survival (EFS) rates were 87 percent and 78 percent, and freedom from TLR (target lesion revascularization) was 89 percent and 82 percent. Clinical measures that included ankle-brachial index, Rutherford score, and walking distance and speed scores showed significant improvement at six and 12 months and were maintained through 24 months. (PR Newswire)
Tekmira Presents Data Demonstrating Further Increases in SNALP Potency Feb 24, 2009
In his talk entitled "TLR Mediated Immune Responses to siRNA Based Drugs" Dr. MacLachlan described the techniques developed by Tekmira to monitor this aspect of siRNA-based drug safety, a key component in their development. Dr. Mark J. Murray, Tekmira's President and CEO, said "These new improvements have the potential to expand the opportunity of systemic RNAi drugs and supports Tekmira as a leader in the field. We expect our research efforts will continue to make these technology advances... (CCNMatthews Press Releases)
Opsona Therapeutics Closes EUR18M Funding Feb 18, 2009
Opsona's lead product, a fully humanised monoclonal antibody (OPN-305) to a key toll-like receptor (TLR) target, has demonstrated efficacy in a number of animal models and will start pivotal clinical trials in 2010 ... " Notes to Editors: About Opsona Therapeutics Opsona is a drug development company, focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases. The company was founded in 2004 with three of Trinity College Dublin's respected Immunologists... (PR Newswire)
